New hope when CAR-T fails: trial tests Next-Gen treatment for tough myeloma cases
NCT ID NCT07009899
Summary
This study is testing an experimental drug called linvoseltamab for people with multiple myeloma whose cancer has returned after receiving a specific type of CAR-T cell therapy. The trial aims to see if this new treatment can help control the disease and is safe for these patients. It will include about 34 adults whose last treatment was BCMA CAR-T therapy at least six months ago.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.